Summary: Study K36-MCRPC-001 is the first in human clinical trial testing KTX-2001 alone and with darolutamide in men with metastatic castration-resistant pros...
Summary: The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's ...
Summary: The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD...
Summary: A single-center phase Ib/II dose escalation and dose-expansion clinical trial of REGN5678 plus cemiplimab...
Summary: This Phase 1 study will evaluate the safety, tolerability, and preliminary effectiveness of AB001, an alpha-emitting radioligand targeting prostate-sp...
Summary: The purpose of the study is to examine the clinical and biological effects of 177Lu-PSMA-617 in mCRPC patients with cytopenia[s]....
Summary: The purpose of this study is to find out whether talazoparib in combination with enzalutamide or talazoparib alone delays cancer progression in people...
Summary: This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activa...
Summary: The purpose of this study is to determine whether [225Ac]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, p...
Summary: The purpose of this study is to evaluate intermittent relugolix + androgen receptor pathway inhibitor (ARPI) in patients with metastatic hormone-sensi...
Summary: This FIH study is designed to assess the safety, tolerability, and preliminary efficacy signals of DS9051b in participants with ACC and mCRPC....
Summary: The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participan...
Summary: A multicenter, open-label, prospective study to investigate immune boost response changes in patients with metastatic castrate-resistant prostate canc...
Summary: This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metast...
This global Phase 3 study is designed to investigate and confirm the benefits and risks associated with TLX591 administered together with standard of care (SoC), as compared to the best SoC alone. The study is being conducted in patients with metastatic…
VISIT
XALute is a research study for men with advanced prostate cancer (cancer has spread to other parts of the body) who have already been treated with chemotherapy.
VISIT
The primary objective of this clinical trial is to assess the effcacy of combining the study medicine (mevrometostat) with a standard therapy (enzalutamide) to treat metastatic castration-resistant prostate cancer (mCRPC) compared to placebo in combination with enzalutamide.
VISIT
The primary goal of this clinical trial is to determine if adding mevrometostat to the standard therapy (enzalutamide) is more effective in treating metastatic castration-sensitive prostate cancer compared to enzalutamide alone with a placebo.
VISIT
The Omaha-003 clinical trial is for participants who have metastatic castration-resistant prostate cancer that failed to respond to drugs or surgery to block the testes from making hormones and after treatment with other drugs for prostate cancer.
VISIT
The primary objective of this clinical trial is to assess the efficacy of combining the study medicine (mevrometostat) with a standard therapy (enzalutamide) to treat metastatic castration-resistant prostate cancer (mCRPC), which will be compared to standard treatments alone (either enzalutamide…
VISIT
The Omaha-004 clinical trial is for participants who have metastatic castration-resistant prostate cancer that failed to respond to drugs or surgery to block the testes from making hormones and after treatment with other drugs for prostate cancer.
VISIT
The goal of substudy 01A is to evaluate the safety and efficacy of opevesostat-based treatment combinations, or as a single agent, in participants with mCRPC.
VISITResearchers seek to learn how safe I-DXd is, by itself or with other drugs, identify the best dose, and see how the cancer responds to treatment for people with metastatic castration resistant prostate cancer (mCRPC)
VISIT
Researchers seek to learn how safe I-DXd is and see how well it works compared to docetaxel, which is a standard treatment for mCRPC.
VISIT
The purpose of this study is to evaluate whether Saruparib (AZD5305) is superior to placebo when added to standard radiation therapy (RT) and androgen deprivation therapy (ADT). The primary measure of effectiveness will be metastasis-free survival in participants with high-risk…
VISIT
